TrueBinding Sharing: NEW DRUG SHOWS POTENTIAL TO REVERSE ALZHEIMER’S DISEASE

​Alzheimer’s Disease (“AD”) is a serious neurodegenerative disorder caused by the progressive loss of neurons in the brain. Two thirds of dementia cases are caused by AD, which typically begins slowly and worsens over time. Symptoms include short term memory loss, problems communicating with language, disorientation (including easily getting lost), mood swings, loss of motivation, self-neglect, and behavioural problems. Eventually, individuals may withdraw from social and family interactions. Gradual loss of bodily functions leads to death, with life expectancy post-diagnosis of 3 to 12 years.

​Up till now, there is no cure for this serious debilitating disease. Worldwide the number of AD patients is projected to rise from 55 million in 2020 to 78 million in 2030. In the USA, an estimated 11% of people over 65 have AD. As people get older, they become more susceptible to AD — e.g. 5.0% of Americans aged 65-74 have AD, with the percentage rising to 13.2% for the 75-84 age group, and 33.4% for those above 85.

​The experimental drug TB006 developed by Californian biotech company TrueBinding Inc. (“TBI”) has been shown to be much safer & more effective than existing approved AD drugs. In Phase 2a clinical trials, TB006 has shown a potential to reverse AD, unlike existing approved drugs which only retard the continuing decline in AD patients’ mental function. Moreover, the drug was tested on a wide range of patients, including those suffering from severe AD, whereas other AD drugs are targeting only patients with early to mild AD.

​The FDA has already authorised TB006 for the Enhanced Access Programme, which allow certified AD patients to receive the drug, even though it has yet to go through Phase 3 clinical trials and receive final approval for market release. TB006 has also been approved by the Hong Kong authorities for a similar scheme, called the Named Patient Programme.

​In this exclusive afternoon tea briefing, TBI’s top management team will explain how the company’s approach differs from that of many other biotech companies that have tried but failed to come up with with effective remedies against this serious debilitating disease. As Singapore, and many other countries have an ageing demographic profile, it’s useful to learn about the latest medical advances that offer some hope to combat this serious disease.

​What You’ll Learn

​At this briefing, TrueBinding’s leadership will share insights into our innovative approach to Alzheimer’s treatment, how we differ from other biotech companies, and our vision for transforming neurodegenerative disease care. This is a unique opportunity to gain firsthand knowledge about our journey and growth and investment plans

​

​Date: Thursday 28th November 2024

​Time: 4.00 pm

​Venue: HGC

​ Suntec City Tower 2, #36-02A,

​ 9 Temasek Boulevard

​ Singapore 038987

​Speakers: George Hong, President, TrueBinding Inc.

​ Martin Schmieg, CEO, TrueBinding Inc.

​John Bumb, Director, TrueBinding Inc.